Concord Biotech Ltd. (CONCORDBIO) AI Stock Analysis

• Market Cap: ₹107.33B
• Dividend Yield: 0.8%
• Average Volume (3M): 12.81K
• Price to Earnings (P/E): 54.6
• Beta (1Y): 0.99
• Revenue Growth: 3.63%
• EPS Growth: -1.21%
• Country: IN
• Employees: 1,377
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 6.30
• Shares Outstanding: 104,616,200
• 10 Day Avg. Volume: 31,605
• 30 Day Avg. Volume: 12,808
• PEG Ratio: 2.27
• Price to Book (P/B): 9.60
• Price to Sales (P/S): 14.50
• P/FCF Ratio: 127.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 39.61
• Revenue Forecast (FY): ₹14.50B

• Rating: 66 Neutral
• Price Target: ₹1,108.00 ▼(-17.23% Downside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is driven primarily by strong financial performance (healthy profitability and a low-leverage balance sheet). This is offset by weak technicals (below key moving averages and negative MACD) and a relatively high P/E with only a modest dividend yield.

Positive Factors

Strong Balance Sheet

Concord's low leverage and high equity ratio provide durable financial flexibility to fund capex, R&D or absorb demand shocks without costly external financing. This stability supports multi-quarter investment plans, lowers refinancing risk, and underpins long-term operational resilience.

Negative Factors

Inconsistent Free Cash Flow Growth

Fluctuating free cash flow growth signals variability in capex timing, working-capital swings, or margin volatility tied to complex fermentation runs. This inconsistency can constrain steady capacity expansion, delay strategic projects, and complicate reliable multi-quarter investment planning.

Concord Biotech Ltd. Business Overview & Revenue Model

Company Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in ...

Read more

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in ...

How the Company Makes Money

Concord Biotech primarily makes money by manufacturing and selling APIs to pharmaceutical companies in domestic and international markets. Its key revenue stream is API sales, where it earns revenue based on contracted/PO-based supply of fermentat...

Read more

Concord Biotech primarily makes money by manufacturing and selling APIs to pharmaceutical companies in domestic and international markets. Its key revenue stream is API sales, where it earns revenue based on contracted/PO-based supply of fermentat...

Concord Biotech Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	11.25B	12.00B	10.17B	8.53B	7.13B	6.17B
Gross Profit	7.51B	7.68B	6.67B	6.61B	5.41B	5.00B
EBITDA	4.56B	5.13B	4.39B	3.53B	2.78B	3.29B
Net Income	3.23B	3.72B	3.08B	2.40B	1.75B	2.35B
Balance Sheet
Total Assets	20.23B	20.34B	17.01B	15.14B	13.13B	11.83B
Cash, Cash Equivalents and Short-Term Investments	3.81B	3.18B	2.86B	1.81B	1.62B	2.01B
Total Debt	16.07M	29.69M	97.38M	315.47M	624.93M	892.83M
Total Liabilities	1.96B	2.22B	1.74B	2.24B	2.10B	1.83B
Stockholders Equity	18.27B	18.13B	15.27B	12.90B	11.03B	9.99B
Cash Flow
Free Cash Flow	975.85M	1.36B	1.80B	1.01B	519.70M	-373.59M
Operating Cash Flow	1.51B	2.47B	2.65B	2.46B	2.07B	1.67B
Investing Cash Flow	-212.84M	-1.63B	-1.55B	-1.58B	-1.12B	-1.95B
Financing Cash Flow	-1.13B	-986.67M	-992.15M	-852.19M	-1.00B	311.24M

Concord Biotech Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1338.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Negative. The current price of 1338.6 is above the 20-day moving average (MA) of 1115.54, above the 50-day MA of 1166.20, and below the 200-day MA of 1486.68, indicating a bearish trend. The MACD of -48.17 indicates Positive momentum. The RSI at 33.05 is Neutral, neither overbought nor oversold. The STOCH value of 18.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CONCORDBIO.

Concord Biotech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CONCORDBIO	66 Neutral	₹107.33B	54.58	―	0.80%	3.63%	-1.21%
BLUEJET	65 Neutral	₹61.90B	57.24	―	0.22%	63.34%	109.89%
BIOCON	63 Neutral	₹570.90B	91.56	―	0.12%	10.62%	-66.88%
JUBLINGREA	61 Neutral	₹92.24B	59.25	―	0.74%	3.80%	64.94%
SYNGENE	61 Neutral	₹157.53B	439.86	―	0.19%	8.57%	-2.93%
PPLPHARMA	55 Neutral	₹188.82B	-41.77	―	0.08%	2.66%	-153.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%